E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Covid-19 infection |
Covid-19-infektio |
|
E.1.1.1 | Medical condition in easily understood language |
Covid-19 infection |
Covid-19-infektio |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to evaluate the therapeutic potential of HCQ, dosed at 300 mg b.i.d. on the first day and then 200 mg b.i.d. for six days (total dose, 3000 mg), in the treatment of adult patients with PCR-confirmed Covid-19 infection in a primary open-care setting, as compared to placebo. |
|
E.2.2 | Secondary objectives of the trial |
Secondary to evaluate the safety and tolerability of HCQ in the treatment Covid-19 infection in a primary care setting, as compared to placebo to collect experience of the use of HCQ in the treatment of Covid-19 infection in outpatients to evaluate the impact of Covid-19 infection and its treatment on the mental health and well-being of the study participants
Exploratory to evaluate the extent and duration of SARS-CoV-2 viral shedding in subjects treated with HCQ compared to placebo to evaluate the extent and time course of SARS-CoV-2 virus-specific antibody responses in serum of subjects treated with HCQ compared to placebo to evaluate the other possible biomarker changes in blood in subjects treated with HCQ compared to placebo to explore the possible effects of genetic variation in drug metabolizing enzymes on HCQ-related outcomes to explore the associations of HCQ-related outcome variables with other patient characteristics, e.g. HCQ concentrations and HLA haplotypes
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subjects over 40 years of age, or 18-40 years of age with one or both of the following: a. diabetes mellitus (type 1 or type 2) b. BMI > 35 kg/m2. 2. Subjects capable of providing independent informed consent and signing the informed consent form (the subjects’ capacity to consent should be determined in accordance with applicable professional standards and will be based on the investigator's judgment). 3. Subjects with symptoms typical of Covid-19 infection, according to criteria specified in the study protocol, with or without known or suspected exposure to the SARS-CoV-2 virus. The onset of symptoms must be within 5 days of enrolment. Study medication may only be started once a positive SARS-CoV-2 PCR test results of a nasopharyngeal swab sample is available; if the first PCR test result is negative, a second sample may be collected and analyzed. 4. Female subjects of child-bearing potential must agree to employ a reliable method of contraception until three months after start of IMP intake. 5. Subject must agree not to share medication with the others.
|
|
E.4 | Principal exclusion criteria |
1. Subjects with suspected severe or moderately severe pneumonia, presenting with any of the following: respiratory rate > 26 breaths/min; significant respiratory distress; or SpO2 ≤94 % on room air; 2. Subjects requiring treatment in the hospital, according to the treating physician’s judgement; 3. Subjects having any contraindication to treatment with HCQ, such as a long QTc interval (>450 ms in men, >470 ms in women), porphyria, epilepsy, severe renal insufficiency; 4. Screening 12-lead ECG results showing evidence of clinically significant disturbances of cardiac rhythm or impulse conduction. Atrial fibrillation, paroxysmal supraventricular tachycardia or supraventricular extrasystoles are not exclusionary; 5. Cardiac insufficiency of NYHA Class 3-4; 6. History of stroke, within 6 months of screening; 7. Subjects with a history of seizures within one year of screening; 8. Subjects with a history of drowning accident; 9. Any psychiatric diagnosis or symptoms (e.g., hallucinations, major depression, delusions, schizophrenia, bipolar disorder) that, in the opinion of the investigator, could interfere with study procedures or assessments or subject safety; 10. Disorder related to alcohol or drug abuse, as defined in DSM-5-TR, within one year prior to screening; 11. Evidence of current or history of any significant autoimmune disease that, in the opinion of the investigator, could interfere with evaluation of the study results or constitute a health hazard for the subject; 12. Evidence of an immune system that is compromised; including, but not limited to, a diagnosis of HIV; or the subject has been splenectomised or has received an organ transplant (corneal transplants excluded), or is receiving chronic systemic immunosuppressive medication; 13. Evidence of current clinically significant and possibly unstable pulmonary, gastrointestinal, renal, hepatic, endocrine, haematological or cardiovascular system disease or metabolic disturbance; 14. Diagnosis of cancer (haematological or solid tumour) for which the subject is currently being treated, or for which there is evidence of active disease. Subjects with local prostate cancer or local dermatological tumours, such as basal or squamous cell carcinoma, may be included; 15. Any clinically significant abnormalities in laboratory tests, vital signs, ECG or physical examination findings at screening that in the opinion of the investigator require further investigation or treatment or may interfere with study procedures or safety. These may include, but are not limited to, the following: a. estimated glomerular filtration ratio (eGFR) < 30 ml/min/1.73 m2, based on the CKD-EPI equation; b. a plasma total bilirubin value >2 times the upper limit of the reference range; c. plasma alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >3 times the upper limit of the reference range; 16. Current or anticipated use or recent prior use (pre-study time limits specified in Section 5.4 of the protocol) of disallowed concomitant treatment; use of concomitant medications that prolong the QTc interval is not allowed (see Appendix 1); 17. Having received in another clinical trial any other investigational medication (unless it can be documented that the subject received only placebo) within 3 months or 5 half-lives (whichever is longer) before screening; 18. Disease or medication that, in the opinion of the investigator, could seriously impact the assessments of safety, tolerability or efficacy. 19. Pregnancy or breast-feeding.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of the study is number of hospitalizations due to Covid-19 infection within four weeks of entry into the study; the study hypothesis is that treatment with HCQ will reduce the risk of hospitalization because of Covid-19 infection, and the sample size estimate of the study is based on the need to test this hypothesis.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary endpoint will be determined by evaluating the patient records, including information collected from health-related registers (the Care Register for Health Care and death certificates archived by Statistics Finland), throughout the treatment period (4 weeks after the first IMP administration) |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints of the study are: - duration and severity of Covid-19-related symptoms, as reported by the participants in the form of daily self-assessments; - number of Intensive Care Unit treatment episodes due to Covid-19 infection within four weeks of entry into the study; - number of deaths due to Covid-19 infection within four weeks of entry into the study; - number of hospitalizations due to Covid-19 infection within three months of entry into the study; - number of Intensive Care Unit treatment episodes due to Covid-19 infection within three months of entry into the study; - number of deaths due to Covid-19 infection within three months of entry into the study; - number of treatment-related adverse events (AEs) and serious AEs (SAEs); - number of participants with treatment-related AEs and SAEs; - all-cause mortality within six months of entry into the study (including post-study follow-up of consenting participants); - all-cause hospitalizations within six months of entry into the study (including post-study follow-up of consenting participants); and - self-assessed symptoms of anxiety of the study participants, as assessed with repeated administration of the Generalized Anxiety Disorder 7-item Scale (GAD-7).
The exploratory endpoints of the study include the following: - extent and duration of SARS-CoV-2 viral shedding, as evaluated with PCR testing of nasopharyngeal swab samples; - extent and time course of SARS-CoV-2 virus-specific antibody responses in serum; - possible other biomarker changes in blood in study subjects.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
During the first two weeks of the treatment period, the subjects are asked to report their symptoms (including body temperature and SpO2) ) in the form of daily self-assessments and daily telephone contacts. At the 2-week and 4-week visits, the subjects will complete GAD-7 questionnaire and undergo the laboratory (the safety, antibody, biomarker, SARS-CoV-2 PCR and HCQ concentration) assessments. Vital signs (body temperature and SpO2) are measured at the 2-week visit. AEs will be collected from informed consent until the end of the follow-up period. The patient records will be evaluated, including information collected from health-related registers (the Care Register for Health Care and death certificates archived by Statistics Finland), until 6 months after start of IMP intake. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will end when register-based follow-up of the last enrolled participant will end. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |